Insider Selling: Regeneron Pharmaceuticals Inc (REGN) Chairman Sells 74,670 Shares of Stock
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Chairman P Roy Vagelos sold 74,670 shares of the company’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $367.22, for a total transaction of $27,420,317.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
P Roy Vagelos also recently made the following trade(s):
- On Thursday, June 21st, P Roy Vagelos sold 74,710 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $327.87, for a total transaction of $24,495,167.70.
Regeneron Pharmaceuticals traded down $1.06, hitting $365.21, on Wednesday, Marketbeat Ratings reports. 595,832 shares of the company were exchanged, compared to its average volume of 921,684. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $526.12. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.94 and a current ratio of 3.59. The firm has a market capitalization of $39.99 billion, a price-to-earnings ratio of 27.31, a price-to-earnings-growth ratio of 1.33 and a beta of 1.36.
Hedge funds have recently modified their holdings of the stock. Dynasty Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $313,000. Pin Oak Investment Advisors Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $152,000. Macquarie Group Ltd. increased its position in Regeneron Pharmaceuticals by 102.5% during the fourth quarter. Macquarie Group Ltd. now owns 54,124 shares of the biopharmaceutical company’s stock worth $20,139,000 after purchasing an additional 27,393 shares during the last quarter. Westwood Holdings Group Inc. acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $2,384,000. Finally, MetLife Investment Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $8,961,000. 66.22% of the stock is owned by hedge funds and other institutional investors.
Several analysts have issued reports on REGN shares. Credit Suisse Group reduced their price target on shares of Regeneron Pharmaceuticals from $440.00 to $420.00 and set a “buy” rating on the stock in a report on Tuesday, April 17th. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 9th. Guggenheim downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, May 1st. BidaskClub raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 28th. Finally, UBS Group raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Wednesday, June 27th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $420.68.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.